作者: Benedito A Carneiro , Jason B Kaplan , Francis J Giles
DOI: 10.1586/17474086.2015.1041910
关键词:
摘要: Current treatment recommendations for chronic myeloid leukemia (CML) are guided by results from multiple clinical trials involving tyrosine kinase inhibitors that target BCR-ABL1. Consideration of the unique benefits and potential risks associated with each inhibitor approved CML is crucial physicians when recommending most appropriate therapy patient. Monitoring prompt management adverse events may increase adherence to optimize patient outcomes. Here we provide an overview efficacy safety CML, as well key reported these agents in patients CML.